A Pharmacokinetic Study of Tulisokibart Administered Subcutaneously Via Autoinjector or Syringe in Healthy Adult Participants
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Tulisokibart (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 03 Sep 2024 New trial record